Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rbd7022
- Development stage
- Phase 3
- Lead developer
- Suzhou Ribo Life Science
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
RBD7022 is a GalNAc-conjugated small interfering RNA (siRNA) drug developed by Suzhou Ribo Life Science for the treatment of hyperlipidemia, including familial and non-familial hypercholesterolemia and mixed hyperlipidemia. It targets proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA in hepatocytes via an RNA interference mechanism to inhibit PCSK9 protein expression. This inhibition reduces lysosomal degradation of low-density lipoprotein receptors (LDL-R), increases LDL-R on liver cell surfaces, and lowers blood levels of LDL cholesterol (LDL-C). The drug is administered subcutaneously and utilizes proprietary liver-targeting delivery technology. Clinical trials have shown that a single administration can sustain efficacy for several months with over 50% reduction in LDL-C levels[3][4][5][6].
- Other names
- SR-043SR043SR 043
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on rbd7022.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rbd7022.